Revvity Inc. $RVTY Position Cut by Candriam S.C.A.

Key Points

• Candriam S.C.A. reduced its holdings in Revvity Inc. by 24.4%, selling 3,048 shares and now owning a total of 9,430 shares valued at approximately $998,000.
• Analysts have revised their price targets for Revvity, with Raymond James lowering it to $115.00, while JPMorgan Chase set theirs at $100.00 as they maintain a "neutral" rating on the stock.
• Revvity announced a quarterly dividend of $0.07, to be paid on November 7th, reflecting an annualized dividend yield of 0.3% and a payout ratio of 11.86%.

Candriam S.C.A. trimmed its stake in Revvity Inc. (NYSE:RVTY - Free Report) by 24.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 9,430 shares of the company's stock after selling 3,048 shares during the period. Candriam S.C.A.'s holdings in Revvity were worth $998,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in RVTY. Raymond James Financial Inc. bought a new position in shares of Revvity in the fourth quarter worth approximately $2,248,000. Mariner LLC grew its position in shares of Revvity by 9.8% during the 4th quarter. Mariner LLC now owns 7,746 shares of the company's stock valued at $865,000 after acquiring an additional 689 shares during the period. Marshall Wace LLP lifted its position in shares of Revvity by 4.6% during the 4th quarter. Marshall Wace LLP now owns 3,556 shares of the company's stock valued at $397,000 after buying an additional 156 shares in the last quarter. OneDigital Investment Advisors LLC bought a new stake in Revvity during the 4th quarter worth approximately $220,000. Finally, Hsbc Holdings PLC raised its position in shares of Revvity by 8.5% during the 4th quarter. Hsbc Holdings PLC now owns 157,655 shares of the company's stock valued at $17,594,000 after purchasing an additional 12,334 shares during the period. Institutional investors own 86.65% of the company's stock.

Revvity Price Performance

Shares of NYSE RVTY traded up $0.29 during midday trading on Friday, hitting $89.52. The company had a trading volume of 372,350 shares, compared to its average volume of 1,176,235. The firm has a market capitalization of $10.39 billion, a price-to-earnings ratio of 37.96, a price-to-earnings-growth ratio of 2.38 and a beta of 0.91. Revvity Inc. has a twelve month low of $85.12 and a twelve month high of $129.50. The business has a 50-day simple moving average of $94.21 and a two-hundred day simple moving average of $98.26. The company has a quick ratio of 2.75, a current ratio of 3.33 and a debt-to-equity ratio of 0.43.

Revvity (NYSE:RVTY - Get Free Report) last announced its earnings results on Monday, July 28th. The company reported $1.18 EPS for the quarter, beating analysts' consensus estimates of $1.14 by $0.04. The firm had revenue of $720.28 million for the quarter, compared to analysts' expectations of $711.26 million. Revvity had a return on equity of 7.66% and a net margin of 10.19%.Revvity's quarterly revenue was up 4.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.22 EPS. Revvity has set its FY 2025 guidance at 4.850-4.950 EPS. Equities research analysts anticipate that Revvity Inc. will post 4.94 earnings per share for the current year.

Revvity Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, November 7th. Investors of record on Friday, October 17th will be given a $0.07 dividend. The ex-dividend date of this dividend is Friday, October 17th. This represents a $0.28 annualized dividend and a dividend yield of 0.3%. Revvity's dividend payout ratio (DPR) is currently 11.86%.

Analysts Set New Price Targets

A number of research analysts have recently commented on RVTY shares. Raymond James Financial reiterated an "outperform" rating and set a $115.00 target price (down from $120.00) on shares of Revvity in a research report on Tuesday, July 29th. Evercore ISI reduced their price objective on shares of Revvity from $116.00 to $115.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. UBS Group raised shares of Revvity from a "neutral" rating to a "buy" rating and dropped their price objective for the company from $145.00 to $115.00 in a report on Thursday, May 1st. Wall Street Zen lowered Revvity from a "buy" rating to a "hold" rating in a report on Sunday, August 3rd. Finally, Stifel Nicolaus decreased their price target on shares of Revvity from $120.00 to $110.00 and set a "hold" rating on the stock in a research note on Tuesday, July 29th. Ten research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Revvity has a consensus rating of "Moderate Buy" and a consensus target price of $120.07.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.